Literature DB >> 22425803

Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review).

Laszlo G Harsing1, G Zsilla, P Matyus, K M Nagy, B Marko, Zs Gyarmati, J Timar.   

Abstract

Glycine is a mandatory positive allosteric modulator of N-methyl-D-aspartate (NMDA)-type ionotropic glutamate receptors in the central nervous system. Elevation of glycine concentrations by inhibition of its reuptake in the vicinity of NMDA receptors may positively influence receptor functions as glycine B binding site on NR1 receptor subunit is not saturated in physiological conditions. Synaptic and extrasynaptic concentrations of glycine are regulated by its type-1 glycine transporter, which is primarily expressed in astroglial and glutamatergic cell membranes. Alteration of synaptic glycine levels may have importance in the treatment of various forms of endogenous psychosis characterized by hypofunctional NMDA receptors. Several lines of evidence indicate that impaired NMDA receptor-mediated glutamatergic neurotransmission is involved in development of the negative (and partly the positive) symptoms and the cognitive deficit in schizophrenia. Inhibitors of glycine transporter type-1 may represent a newly developed therapeutic intervention in treatment of this mental illness. We have synthesized a novel series of N-substituted sarcosines, analogues of the glycine transporter-1 inhibitor NFPS (N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine). Of the pyridazinone-containing compounds, SzV-1997 was found to be a potent glycine transporter-1 inhibitor in rat brain synaptosomes and it markedly increased extracellular glycine concentrations in conscious rat striatum. SzV-1997 did not exhibit toxic symptoms such as hyperlocomotion, restless movements, respiratory depression, and lethality, characteristic for NFPS. Besides pyridazinone-based, sarcosine-containing glycine transporter-1 inhibitors, a series of substrate-type amino acid inhibitors was investigated in order to obtain better insight into the ligand-binding characteristics of the substrate binding cavity of the transporter.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425803     DOI: 10.1556/APhysiol.99.2012.1.1

Source DB:  PubMed          Journal:  Acta Physiol Hung        ISSN: 0231-424X


  3 in total

1.  Chronic adolescent exposure to ∆9-tetrahydrocannabinol decreases NMDA current and extrasynaptic plasmalemmal density of NMDA GluN1 subunits in the prelimbic cortex of adult male mice.

Authors:  Virginia M Pickel; Faye Bourie; June Chan; Ken Mackie; Diane A Lane; Gang Wang
Journal:  Neuropsychopharmacology       Date:  2019-07-19       Impact factor: 7.853

2.  Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions.

Authors:  Adrienn Hanuska; Gábor Szénási; Mihaly Albert; Laszlo Koles; Agoston Varga; Andras Szabo; Peter Matyus; Laszlo G Harsing
Journal:  Neurochem Res       Date:  2015-09-12       Impact factor: 3.996

Review 3.  Purinergic-Glycinergic Interaction in Neurodegenerative and Neuroinflammatory Disorders of the Retina.

Authors:  Laszlo G Harsing; Gábor Szénási; Tibor Zelles; László Köles
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.